MedTrace Logo

Photobiomodulation Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease

NCT04391712 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-08-05

No results posted yet for this study

Summary

The aim of this study is to evaluate the effectiveness of MLS laser therapy as a treatment for pulmonary complications due to COVID-19 infection.

Conditions

Interventions

DEVICE

MLS Laser

Treatments will be delivered to the participants days 1-4, in a prone position using a 10 by 25 cm laser field across each lung with 7j/cm2 at 1500 Hz.

OTHER

Regular Inpatient Medical Care

Regular inpatient medical care

Sponsors & Collaborators

  • Lowell General Hospital

    lead OTHER

Principal Investigators

  • Scott Sigman, MD · Lowell General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-30
Primary Completion
2020-05-15
Completion
2020-07-16
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04391712 on ClinicalTrials.gov